West Pharmaceutical Services, Inc.
WST · NYSE
Next quarter
Consensus is $2.26 EPS for Dec 2026 across 5 estimates, ranging $2.24 to $2.29.
WST Sep 2026
- 22.02%
- -0.97%
- $2.18
- $2.66
- —
- $874.50M
Reported results
- $874.50M
- 39.73%
- $267.40M
- 30.58%
- $214.00M
- $3.02
Highlights
- Organic growth: Q3 net sales rose 8.7% year over year to $874.5 million; organic sales growth was 11.9%, with volume and mix contributing $58.3 million and price increases $33.6 million.
- EPS beat: Adjusted diluted EPS of $2.66 topped the $2.18 consensus by 22.0% and increased 35.7% year over year. GAAP diluted EPS was $3.02, including a $55.7 million gain on the SmartDose sale.
- HVP Components: Sales increased 19.7% reported and 20.3% organically to $466.7 million, or 53% of company sales; management cited demand for biologics and GLP-1 products and pricing.
- Margin expansion: Gross margin rose to 39.7% from 36.6% a year earlier. Adjusted operating margin expanded to 25.3% from 21.1%, with favorable Proprietary Products mix helping offset weakness in West Vantage.
- Guidance raised: Full-year sales guidance increased to $3.41–$3.42 billion from $3.345–$3.380 billion; adjusted EPS guidance rose to $9.38–$9.48 from $8.85–$9.05.
- Segment divergence: Proprietary Products organic sales grew 16.6% to $728.8 million, while West Vantage organic sales fell 6.6% to $145.7 million.
- SmartDose sale: West completed the sale to AbbVie on July 1 for $126.9 million cash. SmartDose sales were $11.8 million in the quarter, and no further sales are expected for the rest of 2026.
- Capital returns and cash: West repurchased $231 million of shares in Q3 and $685 million year to date; nine-month operating cash flow was $403 million, down from $504 million a year ago.
Analysis
West’s Q3 was an underlying growth and mix-driven margin quarter, with a substantial additional lift to GAAP earnings from the SmartDose sale. Revenue of $874.5 million increased 8.7% year over year, or 11.9% organically, but was nearly flat sequentially versus $872.3 million in Q2. Adjusted diluted EPS of $2.66 beat the $2.18 consensus by 22.0% and rose 35.7% from $1.96 a year ago. GAAP EPS was $3.02, up from $1.92 a year ago and $2.15 in Q2, but includes the $55.7 million pretax gain on the divestiture; adjusted EPS is the cleaner view of ongoing performance.
The core growth engine was Proprietary Products, particularly HVP Components, where organic sales rose 20.3%. This mix helped lift gross margin to 39.7% from 36.6% and adjusted operating margin to 25.3% from 21.1%. West Vantage remained the counterpoint, with organic sales down 6.6% amid a lapsed customer contract and production inefficiencies. West raised full-year sales and adjusted EPS guidance, while lowering its capital spending outlook. The quarter also featured significant shareholder returns: $231 million of buybacks and an 18% increase in the declared quarterly dividend to $0.26 per share.
Proprietary Products growth
Proprietary Products generated $728.8 million of sales, up 12.6% reported and 16.6% organically. HVP Components supplied most of the growth, with continued demand in biologics and GLP-1 products and higher pricing; HVP Delivery Devices also grew strongly after excluding SmartDose and currency effects. Standard Products advanced modestly. Across the company, volume and mix contributed $58.3 million of Q3 growth and price increases contributed $33.6 million.
- HVP Components: Sales were $466.7 million, up 19.7% reported and 20.3% organically; the category represented 53% of company sales.
- HVP Delivery Devices: Sales were $99.1 million, flat reported, but up 26.4% organically excluding foreign exchange and the SmartDose divestiture; growth was driven mainly by Daikyo Crystal Zenith and Administration Systems.
- Standard Products: Sales increased 2.9% reported and 3.1% organically to $163.0 million.
- Market mix: Proprietary Products organic sales grew 23.2% in biologics and 21.4% in pharma, while generics declined 4.5%.
Margins and earnings quality
The operating performance improved alongside the sales mix: consolidated gross profit increased 18.0% year over year to $347.4 million, and gross margin expanded 3.1 percentage points to 39.7%. Adjusted operating profit was $221.5 million, up from $170.1 million, and adjusted operating margin rose 4.2 points to 25.3%. GAAP operating profit of $267.4 million also reflects the SmartDose disposal gain; the adjusted measure removes the net M&A benefit and is more representative of the quarter’s operating trend.
- EPS: Adjusted diluted EPS of $2.66 was 35.7% above the prior-year $1.96 and 22.0% above the $2.18 consensus. GAAP diluted EPS was $3.02 versus $1.92 a year earlier.
- Sequential context: Revenue was up about 0.3% from Q2’s $872.3 million. GAAP diluted EPS increased from $2.15 in Q2, although the Q3 figure includes the SmartDose gain.
- Profitability drivers: Proprietary Products’ gross margin increased to 44.4% from 40.8%, primarily on favorable HVP Components mix and pricing, partly offset by inflation and plant costs.
SmartDose divestiture
The July 1 sale to AbbVie changed both reported earnings and the sales comparison. West received $126.9 million in cash and recognized a $55.7 million pretax gain. The gain contributed to the gap between GAAP operating profit of $267.4 million and adjusted operating profit of $221.5 million; the transaction also carried a one-time $22.4 million tax cost. SmartDose revenue was $11.8 million this quarter versus $29.8 million in the year-ago quarter, so the lower reported sales comparison partly reflects the divestiture rather than underlying demand. West expects no further SmartDose sales in 2026.
- Organic comparison: Consolidated reported sales growth of 8.7% reconciled to 11.9% organic growth after accounting for currency and the SmartDose revenue reduction.
- Transaction proceeds: The $126.9 million sale proceeds were reported in investing cash flows; the $55.7 million accounting gain was excluded from adjusted results.
West Vantage pressure
West Vantage sales declined 7.3% reported and 6.6% organically to $145.7 million. The planned expiration of a continuous glucose monitoring customer contract at one facility was the main sales headwind; higher sales of diabetes and obesity self-injection devices and device components, plus pricing, partially offset it. Profitability weakened as well: segment operating profit fell to $15.5 million from $22.3 million, while gross margin contracted to 16.5% from 19.3%. West attributed the pressure to product mix, inflationary plant costs and ramp-up costs in drug-handling programs; the filing also cites production downtime related to the May cyber incident in the nine-month comparison and says operations have fully recovered.
- Nine-month picture: Organic sales were down 0.2% to $438.0 million, and segment operating profit declined to $44.0 million from $53.6 million.
- Offsetting demand: Sales of self-injection devices for diabetes and obesity and device components increased, but did not fully counter the contract expiration and operating cost pressures.
Outlook and capital
West raised its full-year outlook following the quarter’s sales and adjusted EPS performance, while trimming planned investment. The revised organic sales range implies continued growth after excluding currency and the SmartDose transaction. Share repurchases and the dividend increase were substantial, though nine-month operating cash flow was lower than the prior year as working capital absorbed cash.
- 2026 sales: Guidance increased to $3.41–$3.42 billion from $3.345–$3.380 billion; organic growth guidance rose to 11.3%–11.6% from 10%–11%.
- 2026 adjusted EPS: Guidance increased to $9.38–$9.48 from $8.85–$9.05.
- Capital spending: Guidance was reduced to $215–$220 million from $250–$275 million; year-to-date capital expenditures were $125 million.
- Cash generation and returns: Nine-month operating cash flow was $403.4 million versus $503.7 million a year earlier, reflecting higher receivables and inventory. Buybacks totaled $231 million in Q3 and $685.3 million year to date; the declared Q4 dividend rose 18% to $0.26 per share.
